Atrial natriuretic peptides increase calcitonin gene-related peptide within human circulation.

Journal Article (Journal Article)

Long-acting natriuretic peptide (LANP), vessel dilator, and atrial natriuretic factor (ANF) (each infused at 100 ng/kg body weight [BW].min for 60 minutes) increased the circulating concentration of calcitonin gene-related peptide (CGRP) threefold to fourfold in 30 healthy humans. Within 30 minutes of stopping ANF infusion, the CGRP circulating concentration had returned to preinfusion levels, whereas its increase secondary to the other atrial peptides was still significant 2 to 3 hours after cessation of their infusions. There was a 50% decreased excretion (P < .001) of CGRP into the urine secondary to LANP and vessel dilator, which correlated with the increase of CGRP in the circulation. The ANF-induced 50% decreased CGRP excretion occurred after the circulating concentration of CGRP had returned to preinfusion levels. Kaliuretic peptide did not affect CGRP circulating concentration or excretion into urine. These data suggest that LANP and vessel dilator inhibit the metabolic breakdown of CGRP as part of their mechanism of increasing CGRP in plasma, whereas the ANF effect of increasing CGRP in plasma appears to be secondary to stimulating the release of CGRP.

Full Text

Duke Authors

Cited Authors

  • Vesely, DL; Overton, RM; McCormick, MT; Schocken, DD

Published Date

  • July 1997

Published In

Volume / Issue

  • 46 / 7

Start / End Page

  • 818 - 825

PubMed ID

  • 9225838

International Standard Serial Number (ISSN)

  • 0026-0495

Digital Object Identifier (DOI)

  • 10.1016/s0026-0495(97)90129-3


  • eng

Conference Location

  • United States